3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
15
Urinary Bladder Neoplasms
14
Carcinoma, Transitional Cell
14
Neoplasms
5
Urologic Neoplasms
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Neoplasms by Site
3
Carcinoma
3
Recurrence
2
Carcinoma in Situ
2
Virus Diseases
1
Urogenital Diseases
1
Neoplasms by Histologic Type
1
Neoplasm Recurrence, Local
1
Mycobacterium Infections
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Disease
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
Interventions
Gemcitabine
2
valrubicin
1
pembrolizumab
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
atezolizumab
1
Tumor Necrosis Factor-alpha
1
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Interferon-beta
1
Immune Checkpoint Inhibitors
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenoviridae Infections
×
Mitomycin
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled